Four large randomized controlled phase III clinical trials have concluded that the efficacy and safety of adding sintilimab or pembrolizumab to standard chemotherapy were superior to chemotherapy alone in untreated locally advanced or metastatic NSCLC patients without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.